Core Viewpoint - NeurAxis, Inc. is actively engaging with investors through a webcast presentation and one-on-one meetings at the Lytham Partners Fall 2025 Investor Conference, highlighting its focus on neuromodulation therapies for chronic conditions [1][2][3]. Company Overview - NeurAxis, Inc. specializes in medical technology, particularly in neuromodulation therapies aimed at treating chronic and debilitating conditions in both children and adults [4]. - The company is advancing its proprietary IB-Stim™ therapy, which utilizes Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, and is FDA cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21 years [4]. - NeurAxis is conducting additional clinical trials for PENFS targeting various pediatric and adult conditions with significant unmet healthcare needs [4].
NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025